EBS — Emergent BioSolutions Income Statement
0.000.00%
Last trade - 00:00- $980.59m
- $1.38bn
- $1.04bn
- 80
- 95
- 97
- 100
Annual income statement for Emergent BioSolutions, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,555 | 1,774 | 1,118 | 1,049 | 1,044 |
| Cost of Revenue | |||||
| Gross Profit | 1,049 | 1,026 | 424 | 344 | 362 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,122 | 1,432 | 1,288 | 1,702 | 1,128 |
| Operating Profit | 434 | 341 | -170 | -652 | -84.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 407 | 303 | -219 | -731 | -143 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 305 | 220 | -212 | -761 | -191 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 305 | 220 | -212 | -761 | -191 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 305 | 220 | -212 | -761 | -191 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 6.32 | 4.62 | -4.14 | -8.76 | -3.28 |